Purified Proteins
Animal Serum Products
Enzymes
Clotting Proteins
Placenta Extracts
Dried Animal Blood Products
Animal Glands & Organs

About Bovogen Biologicals

Bovogen Biologicals is a privately-owned company based in Melbourne, Australia, that researches, manufactures and supplies highly purified animal proteins, enzymes and animal serum products to the global pharmaceutical, diagnostics and life science communities.

Mission Statement

Bovogen Biologicals aims to be a leading global manufacturer of biological fine chemicals derived from bovine by-products or related raw materials.

Our mission is to guarantee that the quality of our products will meet and exceed our specifications each and every time. We also take pride in our ability to surpass customer expectations for quality, product delivery and service. Bovogen Biologicals' culture is to become an industry partner with our customers, not just a supplier.

Company Overview

Bovogen Biologicals was established in 2001 by Rick Clements for the purpose of manufacturing Australian origin Bovine Serum Albumin (BSA) utilising a proprietary Heat Shock Process.

Since that time, Bovogen Biologicals has expanded considerably in response to the needs of their global customer base, to offer an extensive range of Australian or New Zealand origin purified animal proteins which include Bovine Immunoglobulin, Fibrinogen, Fetuin, Transferrin, Dried Plasma and Haemoglobin and Placenta Extracts.

In support of this exponential growth Bovogen Biologicals' GMP manufacturing facility has more than tripled in size with the addition of an industrial capacity freeze drying suite which is available for contract manufacturing and a purpose built sterile filtration facility where Australian or New Zealand origin Foetal Bovine Serum, (FBS), Newborn Calf Serum (NBCS), Adult Bovine Serum (ABS) and other animal sera such as porcine, ovine and equine, are processed.

Manufactured in Australia under strict GMP, Bovogen Biologicals ensures that their products meet the highest quality standards by using only Australian or New Zealand origin animal derived raw materials, collected from USDA & EU approved facilities. Being of Australian or New Zealand origin, as verified by the availability of complete animal traceability records, products manufactured by Bovogen Biologicals are free of the risk of contamination from any major epidemic diseases, such as BSE & Foot and Mouth Disease which are known to infect livestock in other regions.

This assurance of quality is recognized widely around the world throughout the pharmaceutical and biotechnology industries, where Bovogen Biologicals' products are used in applications from vaccine manufacturing to veterinary diagnostics. Based on its foundation of research and development, Bovogen Biologicals remains committed to working with the biopharmaceutical community through contract manufacturing, collaborative research projects and the formation of industry partnerships and looks forward to continuing to meet its customers' needs for animal derived biologicals.

Advisory Board

Dr David Kennedy: MBBS, FACSP, FACSM, FASMF

Dr. David Kennedy is a qualified medical practitioner with over 25 years experience and training in musculo-skeletal medicine. He has worked at Stanford University, Mayo Clinic and the University of Toronto. More recently he has been involved in the development and commercialization of a number of Biotechnology companies in Australia and the Asia-Pacific region.

Dr. Kennedy was a founding director of Genesis Biomedical Ltd, President and CEO of Codon AG Tissue Engineering in the Asia Pacific region and a founder, director and COO of CollTech Australia Ltd. He is currently the General Manager of Biotechnology Development Pty Ltd and Australian Biotechnology Park Pty Ltd. He is also the co-founder and director of Felix Capital Investments Limited, a Singapore based capital investment company.

He has lived and worked in North America, Europe and Asia combining his medical and scientific expertise with his commercial and marketing skills.

Dr. Ted Stelmasiak: DVM, PhD, MACVSc

Dr. Stelmasiak is the founder and Chief Executive Officer of Glutagen Pty Ltd, a company specializing in the development of treatments for Coeliacs disease. Dr. Stelmasiak was also a founding Director and former Director of Research of Anadis Limited.
He is veterinary pathologist with over 25 years experience who has published over 60 scientific papers, filed several patents and developed a number of commercially viable biopharmaceutical products.

Dr Neil H. Goss: B.Sc., B.Sc. (Hons), Ph.D.

Dr Goss is Executive Director of Further Options Pty. Ltd., a biotechnology consulting company, and Director of Lynx Biopharmaceutical Pty. Ltd., a company specializing in the sales and marketing of vaccines and plasma products.
He has over 25 years of experience in the plasma fractionation and biotechnology industries and was formerly Director of Research and Development at CSL Bioplasma. Dr Goss has broad experience in scientific, technical and management areas and consults widely to the national and international healthcare community.